Treatment of Nonmetastatic Castration Resistant Prostate Cancer

被引：1

作者：

Luo, Jia ^{[1
]}

Beer, Tomasz M. ^{[2
]}

Graff, Julie N. ^{[2
,3
]}

机构：

[1] Oregon Hlth & Sci Univ, Dept Med, Portland, OR 97201 USA

[2] Oregon Hlth & Sci Univ, Knight Canc Inst, Portland, OR 97201 USA

[3] VA Portland Hlth Care Syst, Portland, OR USA

来源：

ONCOLOGY-NEW YORK | 2016年 / 30卷 / 04期

关键词：

METASTASIS-FREE SURVIVAL; ANDROGEN-RECEPTOR GENE; ANTIANDROGEN WITHDRAWAL; PHASE-III; MEN; THERAPY; HORMONE; ENZALUTAMIDE; BICALUTAMIDE; COMBINATION;

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Patients with nonmetastatic castration-resistant prostate cancer (CRPC) are a heterogeneous population with regard to risk of progression to metastatic disease. Treatment selection for nonmetastatic CRPC must balance the risk of disease progression with the side effects of available therapies. Several medication classes are available for use in treating these patients, and other newer agents are under active clinical trial investigation. Here we review current therapies for nonmetastatic CRPC and discuss the recently completed and ongoing trials for this emerging disease state.

引用

页码：336 / 344

页数：9

共 50 条

[21] Treatment patterns and outcomes in patients with nonmetastatic castration-resistant prostate cancer in the United States
Swami, Umang
Hong, Agnes
Diessner, Brandon
Young, Christopher
Bunner, Scott H.
Xie, Bin
Ramaswamy, Krishnan
Chastek, Benjamin
El Chaar, Nader
Gupta, Sumati
FUTURE ONCOLOGY, 2024, 20 (32) : 2467 - 2480
[22] Nonmetastatic Castration-resistant Prostate Cancer: A Modern Perspective
Cancian, Madeline
Renzulli, Joseph F., II
UROLOGY, 2018, 116 : 13 - 16
[23] Apalutamide, darolutamide and enzalutamide in nonmetastatic castration-resistant prostate cancer: a meta-analysis
Roumiguie, Mathieu
Paoletti, Xavier
Neuzillet, Yann
Mathieu, Romain
Vincendeau, Sebastien
Kleinclauss, Francois
Mejean, Arnaud
Guy, Laurent
Timsit, Marc Olivier
Lebret, Thierry
FUTURE ONCOLOGY, 2021, 17 (14) : 1811 - 1823
[24] Patient and caregiver benefit-risk preferences for nonmetastatic castration-resistant prostate cancer treatment
Srinivas, Sandy
Mohamed, Ateesha F.
Appukkuttan, Sreevalsa
Botteman, Marc
Ng, Xinyi
Joshi, Namita
Tsai, Jui-Hua
Fang, Jarjieh
Waldeck, A. Reginald
Simmons, Stacey J.
CANCER MEDICINE, 2020, 9 (18): : 6586 - 6596
[25] Matching-adjusted indirect treatment comparison of the efficacy of enzalutamide versus apalutamide for the treatment of nonmetastatic castration-resistant prostate cancer
Tombal, B.
Sternberg, C. N.
Hussain, M.
Ganguli, A.
Li, Y.
Sandin, R.
Bhadauria, H.
Oh, M.
Saad, F.
ESMO OPEN, 2022, 7 (03)
[26] Budget impact analysis of darolutamide for treatment of nonmetastatic castration-resistant prostate cancer
Appukkuttan, Sreevalsa
Farej, Ryan
Miles, LaStella
Purser, Molly
Wen, Lonnie
JOURNAL OF MANAGED CARE & SPECIALTY PHARMACY, 2021, 27 (02) : 166 - 174
[27] Budget Impact of Enzalutamide for Nonmetastatic Castration-Resistant Prostate Cancer
Schultz, Neil M.
O'Day, Ken
Sugarman, Rebecca
Ramaswamy, Krishnan
JOURNAL OF MANAGED CARE & SPECIALTY PHARMACY, 2020, 26 (04) : 538 - 549
[28] Salvage Radical Prostatectomy in Nonmetastatic Castration-Resistant Prostate Cancer
Lopez-Fontana, Gaston
Manuel Guglielmi, Juan
Lopez-Fontana, Rodrigo
Lis Hinojosa-Jury, Mariana
Lopez-Fontana, Constanza
Daniel Lopez-Laur, Jose
ARCHIVOS ESPANOLES DE UROLOGIA, 2022, 75 (07): : 638 - 641
[29] Castration-Resistant Prostate Cancer: Mechanisms, Targets and Treatment
Mansinho, Andre
Macedo, Daniela
Fernandes, Isabel
Costa, Luis
MOLECULAR & DIAGNOSTIC IMAGING IN PROSTATE CANCER: CLINICAL APPLICATIONS AND TREATMENT STRATEGIES, 2019, 1126 : 117 - 133
[30] Secondary hormonal manipulation in castration resistant prostate cancer
Al-Asaaed, Sohaib
Winquist, Eric
CANADIAN JOURNAL OF UROLOGY, 2014, 21 : 37 - 41

← 1 2 3 4 5 →